NCT06550921View on ClinicalTrials.gov

Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma

NARecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

August 1, 2026

Study Completion Date

August 30, 2027

Conditions
Advanced Hepatocellular CarcinomaOligometastasisAblationAnti-PD1 AntibodyLenvatinib
Interventions
PROCEDURE

ablation of oligometastasis

The oligometastasis of hepatocellular carcinoma are ablation completely by ablation (including microwave ablation, radiofrequency ablation, and cryoablation)

Trial Locations (1)

100853

RECRUITING

Chinese PLA General hospital, Beijing

All Listed Sponsors
collaborator

Chinese PLA General Hospital

OTHER

lead

Sun Yat-sen University

OTHER